PL446441A1 - 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego - Google Patents

2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego

Info

Publication number
PL446441A1
PL446441A1 PL446441A PL44644123A PL446441A1 PL 446441 A1 PL446441 A1 PL 446441A1 PL 446441 A PL446441 A PL 446441A PL 44644123 A PL44644123 A PL 44644123A PL 446441 A1 PL446441 A1 PL 446441A1
Authority
PL
Poland
Prior art keywords
prevention
treatment
vascular endothelial
diseases associated
phytyl
Prior art date
Application number
PL446441A
Other languages
English (en)
Inventor
Stefan CHŁOPICKI
Szczepan Zapotoczny
Anna KIEROŃSKA-RUDEK
Agnieszka KIJ
Anna BAR
Małgorzata JANIK-HAZUK
Justyna BEDNORZ
Original Assignee
Chde Polska Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chde Polska Spółka Akcyjna filed Critical Chde Polska Spółka Akcyjna
Priority to PL446441A priority Critical patent/PL446441A1/pl
Priority to PCT/PL2024/000056 priority patent/WO2025084940A1/en
Publication of PL446441A1 publication Critical patent/PL446441A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia jest związek do stosowania w leczeniu chorób lub zapobieganiu chorobom przebiegających z dysfunkcją śródbłonka naczyniowego, przy czym jest on dostarczany w nanokapsułach o średnicy nie większej niż 1 µm, zawierających lipofilowy rdzeń i hydrofilową powłokę, przy czym nanokapsuły przeznaczone są do podawania doustnego.
PL446441A 2023-10-20 2023-10-20 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego PL446441A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL446441A PL446441A1 (pl) 2023-10-20 2023-10-20 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego
PCT/PL2024/000056 WO2025084940A1 (en) 2023-10-20 2024-10-18 2-methyl-3-phytyl-1,4-naphthoquinone for use in the treatment or prevention of diseases with dysfunction of vascular endothelium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL446441A PL446441A1 (pl) 2023-10-20 2023-10-20 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego

Publications (1)

Publication Number Publication Date
PL446441A1 true PL446441A1 (pl) 2025-04-22

Family

ID=93939479

Family Applications (1)

Application Number Title Priority Date Filing Date
PL446441A PL446441A1 (pl) 2023-10-20 2023-10-20 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego

Country Status (2)

Country Link
PL (1) PL446441A1 (pl)
WO (1) WO2025084940A1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017014655A1 (en) * 2015-07-17 2017-01-26 Uniwersytet Jagiellonski Nanocapsule for delivery of lipophilic compound and process of preparation thereof
WO2019191773A1 (en) * 2018-03-30 2019-10-03 Kaydence Pharma As Rapidly improving vascular conditions by administering vitamin k

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220182D0 (en) * 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
US20180199610A1 (en) * 2015-02-20 2018-07-19 Vitak B.V. Vitamin k and capillary function
WO2020185088A1 (en) * 2019-03-11 2020-09-17 Kaydence Pharma As Rapidly improving endothelial function, reducing arterial stiffness and reversing calcification of blood vessels by administering vitamin k

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017014655A1 (en) * 2015-07-17 2017-01-26 Uniwersytet Jagiellonski Nanocapsule for delivery of lipophilic compound and process of preparation thereof
WO2019191773A1 (en) * 2018-03-30 2019-10-03 Kaydence Pharma As Rapidly improving vascular conditions by administering vitamin k

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIEROŃSKA-RUDEK, ANNA & KIJ, AGNIESZKA & JANIK-HAZUKA, MAŁGORZATA & BEDNORZ, JUSTYNA & ZAPOTOCZNY, SZCZEPAN & CHLOPICKI, STEFAN, (2022). ENDOTHELIUM-TARGETED DELIVERY OF VITAMIN K1 USING HYALURONAN-BASED CAPSULES.; JULY 2022 CONFERENCE: SHAPING MEDICINAL CHEMISTRY FOR THE NEW DECADE AT: ROME, ITALY *

Also Published As

Publication number Publication date
WO2025084940A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
Bumpus Jr Urinary reflux
US5085650A (en) Gynecological urethral suppository
MA26859A1 (fr) Forme posologique de medicament commandée par un hydrogel.
WO1997048391A3 (en) Methods and compositions comprising r-ibuprofen
CO5150202A1 (es) Composicion de tisu facial y metodo para usarla para el secuestro de irritantes de la piel de la secrecion nasal
DK1276470T3 (da) Smagskaskerende overtrækssammensætning
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
HUP9801324A2 (hu) Eljárás és készlet merevedési zavarok megelőzésére
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
PL446441A1 (pl) 2-metylo-3-fitylo-1,4-naftochinon do stosowania w leczeniu lub zapobieganiu chorób przebiegających z dysfunkcją śródbłonka naczyniowego
DK0615441T3 (da) Ibuprofenholdigt lægemiddel til akut brug og dets anvendelse
CR6834A (es) Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
DE69627160D1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma-butyrobetain für die behandlung von herz-gefäss-erkrankungen
ES2185153T3 (es) Uso de mefloquina(+) para el tratamiento de la malaria.
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
BR0215389A (pt) Agente preventivo ou terapêutico para distúrbio urinário, método para prevenir ou tratar distúrbio urinário, uso de um composto, composto, pró-droga, processo para preparar o composto, medicamento, e, método para triar um composto
Giuliano et al. Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats
Vallada et al. Musical hallucinations triggered by clomipramine?
Ludolph et al. Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic lateral sclerosis?: arguments against
Cherry et al. Upper respiratory tract infections
Day et al. A case of heart block treated with 1-cyclohexyl-2-methylaminopropane (benzedrex)
AR031104A1 (es) Composicion farmaceutica que comprende un carboxialquileter y un agente antihipertensivo, primera composicion para su uso con una segunda composicion que comprenden un agente antihipertensivo y un carboxialquileter respectivamente, equipo que comprende un carboxialquileter y un agente antihipertensi
KR910006270A (ko) 약리적 활성 화합물 제법 및 용도